{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicu6wa67p3crn4eayy72gyuayzuvnb34ma5a2gmla4lncwk35cy64",
    "uri": "at://did:plc:nnaxwirbqywidimahadp42bj/app.bsky.feed.post/3mk636rlisck2"
  },
  "path": "/chiesi-reports-strong-fy2025-financial-and-sustainability-results-and-announces-leadership-transition-highlights/",
  "publishedAt": "2026-04-23T11:04:45.000Z",
  "site": "https://www.cityam.com",
  "tags": [
    "Earnings",
    "Personnel",
    "Product/Service",
    "Sales"
  ],
  "textContent": "Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation",
  "title": "Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights"
}